Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

You don’t have to trust the SA author, you can simply look up the following 2 patents

U.S. Patent 10,385,135 has been granted for the co-formulation of Darzalex and PH20. The priority date for this patent is 01Nov2016 which means its expiry date is 01Nov2036. A patent has also been filed for Phesgo, US 2021/0085597.

And here is what Helen said about this topic during the last CC
Q&A session:

“Charles Duncan

Yes. Hi. Thanks Helen and Elaine for taking the follow-up. A quick question regarding the continuation of royalty growth as a function of co-formulation patents. You mentioned that some had been filed. Do you anticipate being able to say that any of those are public or granted say that publicly over the course the next say two years?

Helen Torley

Yes. The timing says it is not in our control. Obviously, we're thrilled that the partners did file them. It'll be down to the patent office and in part due to the partner strategy. So we can't give you a time for it. But as we're thrilled to see this progress because of the benefit this has both in terms of the opportunities to extend the duration of time look at royalties, but also push the times of the step down. But I can't give you a time window. It'll be on a product by product basis.

Charles Duncan

I know you probably can't disclose identities, but can you say whether or not any of them are on Wave 2 products.

Helen Torley

Yes. I can't say that. We have a relatively small pool of opportunities in terms of that. But just to say, that we are excited that our partners are working very hard with us to find that moment of innovation and novelty that we all feel very strongly about has got a very good chance of getting these cool formulation patents. And we're not done yet. I think that's another core thing to hear. While these several partners have moved forward we continue to be very active with several others. And so you're going to see more and more of these co-formulation patterns being submitted over time based on the novelty that can be found when they're co-formulated with ENHANZE.”